[1]        A. Munck, P.M. Guyre, N.J. Holbrook, Physiological functions of glucocorticoids in stress and their relation to pharmacological actions, Endocr Rev 5(1) (1984) 25-44.
[2]        J.K. Clark, W.T. Schrader, B.W. O'Malley, Mechanism of steroid hormones, in: J.D. Wilson, D.W. Foster (Eds.), Williams Textbook of Endocrinology, WB Sanders Co., Philadelphia, 1992. pp. 35-90.
[3]        D.T. Boumpas, G.P. Chrousos, R.L. Wilder, T.R. Cupps, J.E. Balow, Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates, Ann Intern Med 119(12) (1993) 1198-1208.
[4]        J. Galon, D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein, J.J. O'Shea, G.P. Chrousos, S.R. Bornstein, Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells, FASEB J 16(1) (2002) 61-71.
[5]        D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, et al., The nuclear receptor superfamily: the second decade, Cell 83(6) (1995) 835-839.
[6]        J.W. Thornton, Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions, Proc Natl Acad Sci U S A 98(10) (2001) 5671-5676.
[7]        J.W. Thornton, E. Need, D. Crews, Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling, Science 301(5640) (2003) 1714-1717.
[8]        J.W. Thornton, R. DeSalle, Gene family evolution and homology: genomics meets phylogenetics, Annu Rev Genomics Hum Genet 1 (2000) 41-73.
[9]        S. Kuraku, D. Hoshiyama, K. Katoh, H. Suga, T. Miyata, Monophyly of lampreys and hagfishes supported by nuclear DNA-coded genes, J Mol Evol 49(6) (1999) 729-735.
[10]      J.T. Bridgham, S.M. Carroll, J.W. Thornton, Evolution of hormone-receptor complexity by molecular exploitation, Science 312(5770) (2006) 97-101.
[11]      E.A. Ortlund, J.T. Bridgham, M.R. Redinbo, J.W. Thornton, Crystal structure of an ancient protein: evolution by conformational epistasis, Science 317(5844) (2007) 1544-1548.
[12]      S.M. Hollenberg, C. Weinberger, E.S. Ong, G. Cerelli, A. Oro, R. Lebo, E.B. Thompson, M.G. Rosenfeld, R.M. Evans, Primary structure and expression of a functional human glucocorticoid receptor cDNA, Nature 318(6047) (1985) 635-641.
[13]      C.M. Bamberger, A.M. Bamberger, M. de Castro, G.P. Chrousos, Glucocorticoid receptor ß, a potential endogenous inhibitor of glucocorticoid action in humans, J Clin Invest 95(6) (1995) 2435-2441.
[14]      T. Almlof, J.A. Gustafsson, A.P. Wright, Role of hydrophobic amino acid clusters in the transactivation activity of the human glucocorticoid receptor, Mol Cell Biol 17(2) (1997) 934-945.
[15]      T. Almlof, A.E. Wallberg, J.A. Gustafsson, A.P. Wright, Role of important hydrophobic amino acids in the interaction between the glucocorticoid receptor tau 1-core activation domain and target factors, Biochemistry 37(26) (1998) 9586-9594.
[16]      A. Warnmark, J.A. Gustafsson, A.P. Wright, Architectural principles for the structure and function of the glucocorticoid receptor tau 1 core activation domain, J Biol Chem 275(20) (2000) 15014-15018.
[17]      R. Kumar, D.E. Volk, J. Li, J.C. Lee, D.G. Gorenstein, E.B. Thompson, TATA box binding protein induces structure in the recombinant glucocorticoid receptor AF1 domain, Proc Natl Acad Sci U S A 101(47) (2004) 16425-16430.
[18]      K.J. Howard, S.J. Holley, K.R. Yamamoto, C.W. Distelhorst, Mapping the HSP90 binding region of the glucocorticoid receptor, J Biol Chem 265(20) (1990) 11928-11935.
[19]      R. Schule, P. Rangarajan, S. Kliewer, L.J. Ransone, J. Bolado, N. Yang, I.M. Verma, R.M. Evans, Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor, Cell 62(6) (1990) 1217-1226.
[20]      S.H. Meijsing, M.A. Pufall, A.Y. So, D.L. Bates, L. Chen, K.R. Yamamoto, DNA binding site sequence directs glucocorticoid receptor structure and activity, Science 324(5925) (2009) 407-410.
[21]      R.K. Bledsoe, V.G. Montana, T.B. Stanley, C.J. Delves, C.J. Apolito, D.D. McKee, T.G. Consler, D.J. Parks, E.L. Stewart, T.M. Willson, M.H. Lambert, J.T. Moore, K.H. Pearce, H.E. Xu, Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition, Cell 110(1) (2002) 93-105.
[22]      D.M. Tanenbaum, Y. Wang, S.P. Williams, P.B. Sigler, Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains, Proc Natl Acad Sci U S A 95(11) (1998) 5998-6003.
[23]      S.P. Williams, P.B. Sigler, Atomic structure of progesterone complexed with its receptor, Nature 393(6683) (1998) 392-396.
[24]      N.Z. Lu, J.A. Cidlowski, Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes, Mol Cell 18(3) (2005) 331-342.
[25]      E. Presul, S. Schmidt, R. Kofler, A. Helmberg, Identification, tissue expression, and glucocorticoid responsiveness of alternative first exons of the human glucocorticoid receptor, J Mol Endocrinol 38(1-2) (2007) 79-90.
[26]      J.D. Turner, C.P. Muller, Structure of the glucocorticoid receptor (NR3C1) gene 5' untranslated region: identification, and tissue distribution of multiple new human exon 1, J Mol Endocrinol 35(2) (2005) 283-292.
[27]      G.P. Chrousos, T. Kino, Intracellular glucocorticoid signaling: a formerly simple system turns stochastic, Sci STKE 2005(304) (2005) pe48.
[28]      M. Denis, J.A. Gustafsson, A.C. Wikstrom, Interaction of the Mr = 90,000 heat shock protein with the steroid-binding domain of the glucocorticoid receptor, J Biol Chem 263(34) (1988) 18520-18523.
[29]      M.J. Czar, R.H. Lyons, M.J. Welsh, J.M. Renoir, W.B. Pratt, Evidence that the FK506-binding immunophilin heat shock protein 56 is required for trafficking of the glucocorticoid receptor from the cytoplasm to the nucleus, Mol Endocrinol 9(11) (1995) 1549-1560.
[30]      J.K. Owens-Grillo, K. Hoffmann, K.A. Hutchison, A.W. Yem, M.R. Deibel, Jr., R.E. Handschumacher, W.B. Pratt, The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor, J Biol Chem 270(35) (1995) 20479-20484.
[31]      J.G. Savory, B. Hsu, I.R. Laquian, W. Giffin, T. Reich, R.J. Hache, Y.A. Lefebvre, Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor, Mol Cell Biol 19(2) (1999) 1025-1037.
[32]      J.G. McNally, W.G. Muller, D. Walker, R. Wolford, G.L. Hager, The glucocorticoid receptor: rapid exchange with regulatory sites in living cells, Science 287(5456) (2000) 1262-1265.
[33]      R.J. Hache, R. Tse, T. Reich, J.G. Savory, Y.A. Lefebvre, Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor, J Biol Chem 274(3) (1999) 1432-1439.
[34]      J. Yang, J. Liu, D.B. DeFranco, Subnuclear trafficking of glucocorticoid receptors in vitro: chromatin recycling and nuclear export, J Cell Biol 137(3) (1997) 523-538.
[35]      D.B. DeFranco, Subnuclear trafficking of steroid receptors, Biochem Soc Trans 25(2) (1997) 592-597.
[36]      M. Itoh, M. Adachi, H. Yasui, M. Takekawa, H. Tanaka, K. Imai, Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation, Mol Endocrinol 16(10) (2002) 2382-2392.
[37]      J.M. Holaska, B.E. Black, D.C. Love, J.A. Hanover, J. Leszyk, B.M. Paschal, Calreticulin Is a receptor for nuclear export, J Cell Biol 152(1) (2001) 127-140.
[38]      B.E. Black, J.M. Holaska, F. Rastinejad, B.M. Paschal, DNA binding domains in diverse nuclear receptors function as nuclear export signals, Curr Biol 11(22) (2001) 1749-1758.
[39]      J.M. Holaska, B.E. Black, F. Rastinejad, B.M. Paschal, Ca2+-dependent nuclear export mediated by calreticulin, Mol Cell Biol 22(17) (2002) 6286-6297.
[40]      C.M. Bamberger, H.M. Schulte, G.P. Chrousos, Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids, Endocr Rev 17(3) (1996) 245-261.
[41]      B.A. Lieberman, B.J. Bona, D.P. Edwards, S.K. Nordeen, The constitution of a progesterone response element, Mol Endocrinol 7(4) (1993) 515-527.
[42]      M. Beato, A. Sanchez-Pacheco, Interaction of steroid hormone receptors with the transcription initiation complex, Endocr Rev 17(6) (1996) 587-609.
[43]      V. Giguere, S.M. Hollenberg, M.G. Rosenfeld, R.M. Evans, Functional domains of the human glucocorticoid receptor, Cell 46(5) (1986) 645-652.
[44]      N.J. McKenna, R.B. Lanz, B.W. O'Malley, Nuclear receptor coregulators: cellular and molecular biology, Endocr Rev 20(3) (1999) 321-344.
[45]      R.H. Goodman, S. Smolik, CBP/p300 in cell growth, transformation, and development, Genes Dev 14(13) (2000) 1553-1577.
[46]      X.J. Yang, V.V. Ogryzko, J. Nishikawa, B.H. Howard, Y. Nakatani, A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A, Nature 382(6589) (1996) 319-324.
[47]      J.C. Blanco, S. Minucci, J. Lu, X.J. Yang, K.K. Walker, H. Chen, R.M. Evans, Y. Nakatani, K. Ozato, The histone acetylase PCAF is a nuclear receptor coactivator, Genes Dev 12(11) (1998) 1638-1651.
[48]      C. Leo, J.D. Chen, The SRC family of nuclear receptor coactivators, Gene 245(1) (2000) 1-11.
[49]      C.K. Glass, M.G. Rosenfeld, The coregulator exchange in transcriptional functions of nuclear receptors, Genes Dev 14(2) (2000) 121-141.
[50]      J. Boyes, P. Byfield, Y. Nakatani, V. Ogryzko, Regulation of activity of the transcription factor GATA-1 by acetylation, Nature 396(6711) (1998) 594-598.
[51]      W. Gu, R.G. Roeder, Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, Cell 90(4) (1997) 595-606.
[52]      H. Chen, R.J. Lin, W. Xie, D. Wilpitz, R.M. Evans, Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase, Cell 98(5) (1999) 675-686.
[53]      D.M. Heery, E. Kalkhoven, S. Hoare, M.G. Parker, A signature motif in transcriptional co-activators mediates binding to nuclear receptors, Nature 387(6634) (1997) 733-736.
[54]      C.J. Fry, C.L. Peterson, Chromatin remodeling enzymes: who's on first?, Curr Biol 11(5) (2001) R185-197.
[55]      S.K. Yoshinaga, C.L. Peterson, I. Herskowitz, K.R. Yamamoto, Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors, Science 258(5088) (1992) 1598-1604.
[56]      C. Rachez, L.P. Freedman, Mediator complexes and transcription, Curr Opin Cell Biol 13(3) (2001) 274-280.
[57]      A. Henriksson, T. Almlof, J. Ford, I.J. McEwan, J.A. Gustafsson, A.P. Wright, Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor, Mol Cell Biol 17(6) (1997) 3065-3073.
[58]      A.E. Wallberg, K.E. Neely, A.H. Hassan, J.A. Gustafsson, J.L. Workman, A.P. Wright, Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor tau1 activation domain, Mol Cell Biol 20(6) (2000) 2004-2013.
[59]      H. Ma, H. Hong, S.M. Huang, R.A. Irvine, P. Webb, P.J. Kushner, G.A. Coetzee, M.R. Stallcup, Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins, Mol Cell Biol 19(9) (1999) 6164-6173.
[60]      P. Webb, P. Nguyen, J. Shinsako, C. Anderson, W. Feng, M.P. Nguyen, D. Chen, S.M. Huang, S. Subramanian, E. McKinerney, B.S. Katzenellenbogen, M.R. Stallcup, P.J. Kushner, Estrogen receptor activation function 1 works by binding p160 coactivator proteins, Mol Endocrinol 12(10) (1998) 1605-1618.
[61]      A.E. Wallberg, K.E. Neely, J.A. Gustafsson, J.L. Workman, A.P. Wright, P.A. Grant, Histone acetyltransferase complexes can mediate transcriptional activation by the major glucocorticoid receptor activation domain, Mol Cell Biol 19(9) (1999) 5952-5959.
[62]      A.B. Hittelman, D. Burakov, J.A. Iniguez-Lluhi, L.P. Freedman, M.J. Garabedian, Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins, EMBO J 18(19) (1999) 5380-5388.
[63]      R.B. Lanz, N.J. McKenna, S.A. Onate, U. Albrecht, J. Wong, S.Y. Tsai, M.J. Tsai, B.W. O'Malley, A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex, Cell 97(1) (1999) 17-27.
[64]      A. Benecke, P. Chambon, H. Gronemeyer, Synergy between estrogen receptor α activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2, EMBO Rep 1(2) (2000) 151-157.
[65]      H.M. Reichardt, K.H. Kaestner, J. Tuckermann, O. Kretz, O. Wessely, R. Bock, P. Gass, W. Schmid, P. Herrlich, P. Angel, G. Schutz, DNA binding of the glucocorticoid receptor is not essential for survival, Cell 93(4) (1998) 531-541.
[66]      T.J. Cole, J.A. Blendy, A.P. Monaghan, K. Krieglstein, W. Schmid, A. Aguzzi, G. Fantuzzi, E. Hummler, K. Unsicker, G. Schutz, Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation, Genes Dev 9(13) (1995) 1608-1621.
[67]      H.M. Reichardt, J.P. Tuckermann, M. Gottlicher, M. Vujic, F. Weih, P. Angel, P. Herrlich, G. Schutz, Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor, EMBO J 20(24) (2001) 7168-7173.
[68]      J.N. Miner, K.R. Yamamoto, Regulatory crosstalk at composite response elements, Trends Biochem Sci 16(11) (1991) 423-426.
[69]      M. Karin, L. Chang, AP-1-glucocorticoid receptor crosstalk taken to a higher level, J Endocrinol 169(3) (2001) 447-451.
[70]      P.J. Barnes, M. Karin, Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases, N Engl J Med 336(15) (1997) 1066-1071.
[71]      J.A. Didonato, F. Saatcioglu, M. Karin, Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids, Am J Respir Crit Care Med 154(2 Pt 2) (1996) S11-15.
[72]      A.C. Liberman, J. Druker, F.A. Garcia, F. Holsboer, E. Arzt, Intracellular molecular signaling. Basis for specificity to glucocorticoid anti-inflammatory actions, Ann N Y Acad Sci 1153 (2009) 6-13.
[73]      A.C. Liberman, D. Refojo, J. Druker, M. Toscano, T. Rein, F. Holsboer, E. Arzt, The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction, FASEB J 21(4) (2007) 1177-1188.
[74]      M.M. Reily, C. Pantoja, X. Hu, Y. Chinenov, I. Rogatsky, The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression, EMBO J 25(1) (2006) 108-117.
[75]      N.D. Perkins, The Rel/NF-kB family: friend and foe, Trends Biochem Sci 25(9) (2000) 434-440.
[76]      L.I. McKay, J.A. Cidlowski, Molecular control of immune/inflammatory responses: interactions between nuclear factor-kB and steroid receptor-signaling pathways, Endocr Rev 20(4) (1999) 435-459.
[77]      E. Caldenhoven, J. Liden, S. Wissink, A. Van de Stolpe, J. Raaijmakers, L. Koenderman, S. Okret, J.A. Gustafsson, P.T. Van der Saag, Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids, Mol Endocrinol 9(4) (1995) 401-412.
[78]      J. Liden, F. Delaunay, I. Rafter, J. Gustafsson, S. Okret, A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation, J Biol Chem 272(34) (1997) 21467-21472.
[79]      S. Wissink, E.C. van Heerde, M.L. Schmitz, E. Kalkhoven, B. van der Burg, P.A. Baeuerle, P.T. van der Saag, Distinct domains of the RelA NF-kB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor, J Biol Chem 272(35) (1997) 22278-22284.
[80]      L.I. McKay, J.A. Cidlowski, Cross-talk between nuclear factor-kB and the steroid hormone receptors: mechanisms of mutual antagonism, Mol Endocrinol 12(1) (1998) 45-56.
[81]      K. Ito, P.J. Barnes, I.M. Adcock, Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1ß-induced histone H4 acetylation on lysines 8 and 12, Mol Cell Biol 20(18) (2000) 6891-6903.
[82]      R.M. Nissen, K.R. Yamamoto, The glucocorticoid receptor inhibits NFkB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain, Genes Dev 14(18) (2000) 2314-2329.
[83]      N. Auphan, J.A. DiDonato, C. Rosette, A. Helmberg, M. Karin, Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of I kB synthesis, Science 270(5234) (1995) 286-290.
[84]      P. Herrlich, Cross-talk between glucocorticoid receptor and AP-1, Oncogene 20(19) (2001) 2465-2475.
[85]      H. van Dam, M. Castellazzi, Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis, Oncogene 20(19) (2001) 2453-2464.
[86]      Y. Kamei, L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S.C. Lin, R.A. Heyman, D.W. Rose, C.K. Glass, M.G. Rosenfeld, A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors, Cell 85(3) (1996) 403-414.
[87]      B. Mayr, M. Montminy, Transcriptional regulation by the phosphorylation-dependent factor CREB, Nat Rev Mol Cell Biol 2(8) (2001) 599-609.
[88]      C. Stauber, J. Altschmied, I.E. Akerblom, J.L. Marron, P.L. Mellon, Mutual cross-interference between glucocorticoid receptor and CREB inhibits transactivation in placental cells, New Biol 4(5) (1992) 527-540.
[89]      V.K. Chatterjee, L.D. Madison, S. Mayo, J.L. Jameson, Repression of the human glycoprotein hormone α-subunit gene by glucocorticoids: evidence for receptor interactions with limiting transcriptional activators, Mol Endocrinol 5(1) (1991) 100-110.
[90]      E. Imai, J.N. Miner, J.A. Mitchell, K.R. Yamamoto, D.K. Granner, Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids, J Biol Chem 268(8) (1993) 5353-5356.
[91]      J.L. Liu, D.N. Papachristou, Y.C. Patel, Glucocorticoids activate somatostatin gene transcription through co-operative interaction with the cyclic AMP signalling pathway, Biochem J 301(Pt 3) (1994) 863-869.
[92]      P. ten Dijke, K. Miyazono, C.H. Heldin, Signaling inputs converge on nuclear effectors in TGF-ß signaling, Trends Biochem Sci 25(2) (2000) 64-70.
[93]      A. Hata, G. Lagna, J. Massague, A. Hemmati-Brivanlou, Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor, Genes Dev 12(2) (1998) 186-197.
[94]      S. Bai, X. Shi, X. Yang, X. Cao, Smad6 as a transcriptional corepressor, J Biol Chem 275(12) (2000) 8267-8270.
[95]      S. Bai, X. Cao, A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-ß signaling, J Biol Chem 277(6) (2002) 4176-4182.
[96]      X. Lin, Y.Y. Liang, B. Sun, M. Liang, Y. Shi, F.C. Brunicardi, X.H. Feng, Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription, Mol Cell Biol 23(24) (2003) 9081-9093.
[97]      M. Afrakhte, A. Moren, S. Jossan, S. Itoh, K. Sampath, B. Westermark, C.H. Heldin, N.E. Heldin, P. ten Dijke, Induction of inhibitory Smad6 and Smad7 mRNA by TGF-ß family members, Biochem Biophys Res Commun 249(2) (1998) 505-511.
[98]      K. Miyazono, Positive and negative regulation of TGF-ß signaling, J Cell Sci 113 (2000) 1101-1109.
[99]      T. Ichijo, A. Voutetakis, A.P. Cotrim, N. Bhattachryya, M. Fujii, G.P. Chrousos, T. Kino, The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: potential clinical implications, J Biol Chem 280(51) (2005) 42067-42077.
[100]    J. Lekstrom-Himes, K.G. Xanthopoulos, Biological role of the CCAAT/enhancer-binding protein family of transcription factors, J Biol Chem 273(44) (1998) 28545-28548.
[101]    Y. Nishio, H. Isshiki, T. Kishimoto, S. Akira, A nuclear factor for interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically activate transcription of the rat α1-acid glycoprotein gene via direct protein-protein interaction, Mol Cell Biol 13(3) (1993) 1854-1862.
[102]    M. Boruk, J.G. Savory, R.J. Hache, AF-2-dependent potentiation of CCAAT enhancer binding protein ß-mediated transcriptional activation by glucocorticoid receptor, Mol Endocrinol 12(11) (1998) 1749-1763.
[103]    M.U. De Martino, N. Bhattachryya, S. Alesci, T. Ichijo, G.P. Chrousos, T. Kino, The glucocorticoid receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II interact with and mutually affect each other's transcriptional activities: implications for intermediary metabolism, Mol Endocrinol 18(4) (2004) 820-833.
[104]    C.E. Pierreux, J. Stafford, D. Demonte, D.K. Scott, J. Vandenhaute, R.M. O'Brien, D.K. Granner, G.G. Rousseau, F.P. Lemaigre, Antiglucocorticoid activity of hepatocyte nuclear factor-6, Proc Natl Acad Sci U S A 96(16) (1999) 8961-8966.
[105]    A. Philips, M. Maira, A. Mullick, M. Chamberland, S. Lesage, P. Hugo, J. Drouin, Antagonism between Nur77 and glucocorticoid receptor for control of transcription, Mol Cell Biol 17(10) (1997) 5952-5959.
[106]    S. Sengupta, J.L. Vonesch, C. Waltzinger, H. Zheng, B. Wasylyk, Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells, EMBO J 19(22) (2000) 6051-6064.
[107]    S. Sengupta, B. Wasylyk, Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2, Genes Dev 15(18) (2001) 2367-2380.
[108]    U.R. Chandran, B.S. Warren, C.T. Baumann, G.L. Hager, D.B. DeFranco, The glucocorticoid receptor is tethered to DNA-bound Oct-1 at the mouse gonadotropin-releasing hormone distal negative glucocorticoid response element, J Biol Chem 274(4) (1999) 2372-2378.
[109]    N. Subramaniam, W. Cairns, S. Okret, Glucocorticoids repress transcription from a negative glucocorticoid response element recognized by two homeodomain-containing proteins, Pbx and Oct-1, J Biol Chem 273(36) (1998) 23567-23574.
[110]    G.G. Prefontaine, M.E. Lemieux, W. Giffin, C. Schild-Poulter, L. Pope, E. LaCasse, P. Walker, R.J. Hache, Recruitment of octamer transcription factors to DNA by glucocorticoid receptor, Mol Cell Biol 18(6) (1998) 3416-3430.
[111]    M. Truss, J. Bartsch, A. Schelbert, R.J. Hache, M. Beato, Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo, EMBO J 14(8) (1995) 1737-1751.
[112]    E. Hartig, A.C. Cato, In vivo binding of proteins to stably integrated MMTV DNA in murine cell lines: occupancy of NFI and OTF1 binding sites in the absence and presence of glucocorticoids, Cell Mol Biol Res 40(7-8) (1994) 643-652.
[113]    T.K. Archer, M.G. Cordingley, R.G. Wolford, G.L. Hager, Transcription factor access is mediated by accurately positioned nucleosomes on the mouse mammary tumor virus promoter, Mol Cell Biol 11(2) (1991) 688-698.
[114]    T.J. Chang, B.M. Scher, S. Waxman, W. Scher, Inhibition of mouse GATA-1 function by the glucocorticoid receptor: possible mechanism of steroid inhibition of erythroleukemia cell differentiation, Mol Endocrinol 7(4) (1993) 528-542.
[115]    J. Rosen, J.N. Miner, The search for safer glucocorticoid receptor ligands, Endocr Rev 26(3) (2005) 452-464.
[116]    B.M. Vayssiere, S. Dupont, A. Choquart, F. Petit, T. Garcia, C. Marchandeau, H. Gronemeyer, M. Resche-Rigon, Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo, Mol Endocrinol 11(9) (1997) 1245-1255.
[117]    M.J. Coghlan, P.B. Jacobson, B. Lane, M. Nakane, C.W. Lin, S.W. Elmore, P.R. Kym, J.R. Luly, G.W. Carter, R. Turner, C.M. Tyree, J. Hu, M. Elgort, J. Rosen, J.N. Miner, A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects, Mol Endocrinol 17(5) (2003) 860-869.
[118]    H. Schacke, A. Schottelius, W.D. Docke, P. Strehlke, S. Jaroch, N. Schmees, H. Rehwinkel, H. Hennekes, K. Asadullah, Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects, Proc Natl Acad Sci U S A 101(1) (2004) 227-232.
[119]    K. De Bosscher, W. Vanden Berghe, I.M. Beck, W. Van Molle, N. Hennuyer, J. Hapgood, C. Libert, B. Staels, A. Louw, G. Haegeman, A fully dissociated compound of plant origin for inflammatory gene repression, Proc Natl Acad Sci U S A 102(44) (2005) 15827-15832.
[120]    J.N. Miner, C. Tyree, J. Hu, E. Berger, K. Marschke, M. Nakane, M.J. Coghlan, D. Clemm, B. Lane, J. Rosen, A nonsteroidal glucocorticoid receptor antagonist, Mol Endocrinol 17(1) (2003) 117-127.
[121]    H. Faus, B. Haendler, Post-translational modifications of steroid receptors, Biomed Pharmacother 60(9) (2006) 520-528.
[122]    M. Fu, M. Liu, A.A. Sauve, X. Jiao, X. Zhang, X. Wu, M.J. Powell, T. Yang, W. Gu, M.L. Avantaggiati, N. Pattabiraman, T.G. Pestell, F. Wang, A.A. Quong, C. Wang, R.G. Pestell, Hormonal control of androgen receptor function through SIRT1, Mol Cell Biol 26(21) (2006) 8122-8135.
[123]    M.Y. Kim, E.M. Woo, Y.T. Chong, D.R. Homenko, W.L. Kraus, Acetylation of estrogen receptor α by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor, Mol Endocrinol 20(7) (2006) 1479-1493.
[124]    K. Ito, S. Yamamura, S. Essilfie-Quaye, B. Cosio, M. Ito, P.J. Barnes, I.M. Adcock, Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kB suppression, J Exp Med 203(1) (2006) 7-13.
[125]    N. Nader, G.P. Chrousos, T. Kino, Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications, FASEB J 23(5) (2009) 1572-1583.
[126]    J.S. Takahashi, H.K. Hong, C.H. Ko, E.L. McDearmon, The genetics of mammalian circadian order and disorder: implications for physiology and disease, Nat Rev Genet 9(10) (2008) 764-775.
[127]    M. Doi, J. Hirayama, P. Sassone-Corsi, Circadian regulator CLOCK is a histone acetyltransferase, Cell 125(3) (2006) 497-508.
[128]    V.S. Melvin, C. Harrell, J.S. Adelman, W.L. Kraus, M. Churchill, D.P. Edwards, The role of the C-terminal extension (CTE) of the estrogen receptor α and ß DNA binding domain in DNA binding and interaction with HMGB, J Biol Chem 279(15) (2004) 14763-14771.
[129]    N. Nader, G.P. Chrousos, T. Kino, Interactions of the circadian CLOCK system and the HPA axis, Trends Endocrinol Metab 21(5) (2010) 277-286.
[130]    N. Ismaili, M.J. Garabedian, Modulation of glucocorticoid receptor function via phosphorylation, Ann N Y Acad Sci 1024 (2004) 86-101.
[131]    E. Orti, L.M. Hu, A. Munck, Kinetics of glucocorticoid receptor phosphorylation in intact cells. Evidence for hormone-induced hyperphosphorylation after activation and recycling of hyperphosphorylated receptors, J Biol Chem 268(11) (1993) 7779-7784.
[132]    M.D. Krstic, I. Rogatsky, K.R. Yamamoto, M.J. Garabedian, Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor, Mol Cell Biol 17(7) (1997) 3947-3954.
[133]    Z. Wang, J. Frederick, M.J. Garabedian, Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo, J Biol Chem 277(29) (2002) 26573-26580.
[134]    A.L. Miller, M.S. Webb, A.J. Copik, Y. Wang, B.H. Johnson, R. Kumar, E.B. Thompson, p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211, Mol Endocrinol 19(6) (2005) 1569-1583.
[135]    N. Ismaili, R. Blind, M.J. Garabedian, Stabilization of the unliganded glucocorticoid receptor by TSG101, J Biol Chem 280(12) (2005) 11120-11126.
[136]    T. Kino, T. Ichijo, N.D. Amin, S. Kesavapany, Y. Wang, N. Kim, S. Rao, A. Player, Y.L. Zheng, M.J. Garabedian, E. Kawasaki, H.C. Pant, G.P. Chrousos, Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress, Mol Endocrinol 21(7) (2007) 1552-1568.
[137]    R. Dhavan, L.H. Tsai, A decade of CDK5, Nat Rev Mol Cell Biol 2(10) (2001) 749-759.
[138]    N. Nader, S.S. Ng, G.I. Lambrou, P. Pervanidou, Y. Wang, G.P. Chrousos, T. Kino, Adenosine 5'-monophosphate-activated protein kinase regulates metabolic actions of glucocorticoids by phosphorylating the glucocorticoid receptor through p38 mitogen-activated protein kinase, Mol Endocrinol (in press) (2010).
[139]    A.P. Dennis, B.W. O'Malley, Rush hour at the promoter: how the ubiquitin-proteasome pathway polices the traffic flow of nuclear receptor-dependent transcription, J Steroid Biochem Mol Biol 93(2-5) (2005) 139-151.
[140]    H.K. Kinyamu, J. Chen, T.K. Archer, Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors, J Mol Endocrinol 34(2) (2005) 281-297.
[141]    L.J. Jason, S.C. Moore, J.D. Lewis, G. Lindsey, J. Ausio, Histone ubiquitination: a tagging tail unfolds?, Bioessays 24(2) (2002) 166-174.
[142]    T.G. Gillette, F. Gonzalez, A. Delahodde, S.A. Johnston, T. Kodadek, Physical and functional association of RNA polymerase II and the proteasome, Proc Natl Acad Sci U S A 101(16) (2004) 5904-5909.
[143]    A.D. Wallace, J.A. Cidlowski, Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids, J Biol Chem 276(46) (2001) 42714-42721.
[144]    B.J. Deroo, C. Rentsch, S. Sampath, J. Young, D.B. DeFranco, T.K. Archer, Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking, Mol Cell Biol 22(12) (2002) 4113-4123.
[145]    M.J. Schaaf, J.A. Cidlowski, Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity, Mol Cell Biol 23(6) (2003) 1922-1934.
[146]    T. Kino, S.H. Liou, E. Charmandari, G.P. Chrousos, Glucocorticoid receptor mutants demonstrate increased motility inside the nucleus of living cells: time of fluorescence recovery after photobleaching (FRAP) is an integrated measure of receptor function, Mol Med 10(7-12) (2004) 80-88.
[147]    A.M. Andreou, N. Tavernarakis, SUMOylation and cell signalling, Biotechnol J 4(12) (2009) 1740-1752.
[148]    S. Holmstrom, M.E. Van Antwerp, J.A. Iniguez-Lluhi, Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy, Proc Natl Acad Sci U S A 100(26) (2003) 15758-15763.
[149]    L. Davies, N. Karthikeyan, J.T. Lynch, E.A. Sial, A. Gkourtsa, C. Demonacos, M. Krstic-Demonacos, Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function, Mol Endocrinol 22(6) (2008) 1331-1344.
[150]    S. Tian, H. Poukka, J.J. Palvimo, O.A. Janne, Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor, Biochem J 367(Pt 3) (2002) 907-911.
[151]    Y. Le Drean, N. Mincheneau, P. Le Goff, D. Michel, Potentiation of glucocorticoid receptor transcriptional activity by sumoylation, Endocrinology 143(9) (2002) 3482-3489.
[152]    D.Y. Lin, Y.S. Huang, J.C. Jeng, H.Y. Kuo, C.C. Chang, T.T. Chao, C.C. Ho, Y.C. Chen, T.P. Lin, H.I. Fang, C.C. Hung, C.S. Suen, M.J. Hwang, K.S. Chang, G.G. Maul, H.M. Shih, Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors, Mol Cell 24(3) (2006) 341-354.
[153]    M. Tirard, J. Jasbinsek, O.F. Almeida, T.M. Michaelidis, The manifold actions of the protein inhibitor of activated STAT proteins on the transcriptional activity of mineralocorticoid and glucocorticoid receptors in neural cells, J Mol Endocrinol 32(3) (2004) 825-841.
[154]    S.H. Yang, A.D. Sharrocks, SUMO promotes HDAC-mediated transcriptional repression, Mol Cell 13(4) (2004) 611-617.
[155]    S.R. Holmstrom, S. Chupreta, A.Y. So, J.A. Iniguez-Lluhi, SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX, Mol Endocrinol 22(9) (2008) 2061-2075.
[156]    J.R. Seckl, B.R. Walker, Minireview: 11ß-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action, Endocrinology 142(4) (2001) 1371-1376.
[157]    H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, J.S. Flier, A transgenic model of visceral obesity and the metabolic syndrome, Science 294(5549) (2001) 2166-2170.
[158]    H. Masuzaki, H. Yamamoto, C.J. Kenyon, J.K. Elmquist, N.M. Morton, J.M. Paterson, H. Shinyama, M.G. Sharp, S. Fleming, J.J. Mullins, J.R. Seckl, J.S. Flier, Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice, J Clin Invest 112(1) (2003) 83-90.
[159]    K.I. Kang, X. Meng, J. Devin-Leclerc, I. Bouhouche, A. Chadli, F. Cadepond, E.E. Baulieu, M.G. Catelli, The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter, Proc Natl Acad Sci U S A 96(4) (1999) 1439-1444.
[160]    J. Schneikert, S. Hubner, G. Langer, T. Petri, M. Jaattela, J. Reed, A.C. Cato, Hsp70-RAP46 interaction in downregulation of DNA binding by glucocorticoid receptor, EMBO J 19(23) (2000) 6508-6516.
[161]    S.J. Stohs, B.D. Abbott, F.H. Lin, L.S. Birnbaum, Induction of ethoxyresorufin-O-deethylase and inhibition of glucocorticoid receptor binding in skin and liver of haired and hairless HRS/J mice by topically applied 2,3,7,8-tetrachlorodibenzo-p-dioxin, Toxicology 65(1-2) (1990) 123-136.
[162]    G.I. Sunahara, G.W. Lucier, Z. McCoy, E.H. Bresnick, E.R. Sanchez, K.G. Nelson, Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor, Mol Pharmacol 36(2) (1989) 239-247.
[163]    P.B. Brake, L. Zhang, C.R. Jefcoate, Aryl hydrocarbon receptor regulation of cytochrome P4501B1 in rat mammary fibroblasts: evidence for transcriptional repression by glucocorticoids, Mol Pharmacol 54(5) (1998) 825-833.
[164]    M.J. Czar, M.D. Galigniana, A.M. Silverstein, W.B. Pratt, Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus, Biochemistry 36(25) (1997) 7776-7785.
[165]    L. Whitesell, P. Cook, Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells, Mol Endocrinol 10(6) (1996) 705-712.
[166]    Y. Makino, K. Okamoto, N. Yoshikawa, M. Aoshima, K. Hirota, J. Yodoi, K. Umesono, I. Makino, H. Tanaka, Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system, J Clin Invest 98(11) (1996) 2469-2477.
[167]    T. Miura, R. Ouchida, N. Yoshikawa, K. Okamoto, Y. Makino, T. Nakamura, C. Morimoto, I. Makino, H. Tanaka, Functional Modulation of the Glucocorticoid Receptor and Suppression of NF-kB-dependent Transcription by Ursodeoxycholic Acid, J Biol Chem 276(50) (2001) 47371-47378.
[168]    N. Yoshikawa, Y. Makino, K. Okamoto, C. Morimoto, I. Makino, H. Tanaka, Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor, J Biol Chem 277(7) (2002) 5529-5540.
[169]    S. Takahashi, H. Wakui, J.A. Gustafsson, J. Zilliacus, H. Itoh, Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein, Biochem Biophys Res Commun 274(1) (2000) 87-92.
[170]    T. Kino, D.E. Hurt, T. Ichijo, N. Nader, G.P. Chrousos, Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor, Sci Signal 3(107) (2010) ra8.
[171]    T. Kino, Y.A. Su, G.P. Chrousos, Human glucocorticoid receptor isoform ß: recent understanding of its potential implications in physiology and pathophysiology, Cell Mol Life Sci 66(21) (2009) 3435-3448.
[172]    M.J. Schaaf, D. Champagne, I.H. van Laanen, D.C. van Wijk, A.H. Meijer, O.C. Meijer, H.P. Spaink, M.K. Richardson, Discovery of a functional glucocorticoid receptor ß-isoform in zebrafish, Endocrinology 149(4) (2008) 1591-1599.
[173]    C. Otto, H.M. Reichardt, G. Schutz, Absence of glucocorticoid receptor-ß in mice, J Biol Chem 272(42) (1997) 26665-26668.
[174]    T. Kino, G.P. Chrousos, Glucocorticoid and mineralocorticoid receptors and associated diseases, Essays Biochem 40 (2004) 137-155.
[175]    E. Charmandari, G.P. Chrousos, T. Ichijo, N. Bhattacharyya, A. Vottero, E. Souvatzoglou, T. Kino, The human glucocorticoid receptor (hGR) ß isoform suppresses the transcriptional activity of hGRα by interfering with formation of active coactivator complexes, Mol Endocrinol 19(1) (2005) 52-64.
[176]    R.H. Oakley, C.M. Jewell, M.R. Yudt, D.M. Bofetiado, J.A. Cidlowski, The dominant negative activity of the human glucocorticoid receptor ß isoform. Specificity and mechanisms of action, J Biol Chem 274(39) (1999) 27857-27866.
[177]    L.B. Li, D.Y. Leung, C.F. Hall, E. Goleva, Divergent expression and function of glucocorticoid receptor ß in human monocytes and T cells, J Leukoc Biol 79(4) (2006) 818-827.
[178]    X. Zhang, A.F. Clark, T. Yorio, Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-ß, Invest Ophthalmol Vis Sci 46(12) (2005) 4607-4616.
[179]    T. Kino, I. Manoli, S. Kelkar, Y. Wang, Y.A. Su, G.P. Chrousos, Glucocorticoid receptor (GR) ß has intrinsic, GRα-independent transcriptional activity, Biochem Biophys Res Commun 381(4) (2009) 671-675.
[180]    L.J. Lewis-Tuffin, C.M. Jewell, R.J. Bienstock, J.B. Collins, J.A. Cidlowski, Human glucocorticoid receptor ß binds RU-486 and is transcriptionally active, Mol Cell Biol 27(6) (2007) 2266-2282.
[181]    M. de Castro, S. Elliot, T. Kino, C. Bamberger, M. Karl, E. Webster, G.P. Chrousos, The non-ligand binding ß-isoform of the human glucocorticoid receptor (hGRß): tissue levels, mechanism of action, and potential physiologic role, Mol Med 2(5) (1996) 597-607.
[182]    R.H. Oakley, M. Sar, J.A. Cidlowski, The human glucocorticoid receptor ß isoform. Expression, biochemical properties, and putative function, J Biol Chem 271(16) (1996) 9550-9559.
[183]    T.D. Hinds, Jr., S. Ramakrishnan, H.A. Cash, L.A. Stechschulte, G. Heinrich, S.M. Najjar, E.R. Sanchez, Discovery of glucocorticoid receptor-ß in mice with a role in metabolism, Mol Endocrinol (in press) (2010).
[184]    M. van der Vaart, M.J. Schaaf, Naturally occurring C-terminal splice variants of nuclear receptors, Nucl Recept Signal 7 (2009) e007.
[185]    S. Ogawa, S. Inoue, T. Watanabe, A. Orimo, T. Hosoi, Y. Ouchi, M. Muramatsu, Molecular cloning and characterization of human estrogen receptor ßcx: a potential inhibitor of estrogen action in human, Nucleic Acids Res 26(15) (1998) 3505-3512.
[186]    D. Benbrook, M. Pfahl, A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library, Science 238(4828) (1987) 788-791.
[187]    K. Ebihara, Y. Masuhiro, T. Kitamoto, M. Suzawa, Y. Uematsu, T. Yoshizawa, T. Ono, H. Harada, K. Matsuda, T. Hasegawa, S. Masushige, S. Kato, Intron retention generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway, Mol Cell Biol 16(7) (1996) 3393-3400.
[188]    K.A. Arnold, M. Eichelbaum, O. Burk, Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor, Nucl Recept 2(1) (2004) 1.
[189]    A. Hossain, C. Li, G.F. Saunders, Generation of two distinct functional isoforms of dosage-sensitive sex reversal-adrenal hypoplasia congenita-critical region on the X chromosome gene 1 (DAX-1) by alternative splicing, Mol Endocrinol 18(6) (2004) 1428-1437.
[190]    N. Ohkura, T. Hosono, K. Maruyama, T. Tsukada, K. Yamaguchi, An isoform of Nurr1 functions as a negative inhibitor of the NGFI-B family signaling, Biochim Biophys Acta 1444(1) (1999) 69-79.
[191]    I. Petropoulos, D. Part, A. Ochoa, M.M. Zakin, E. Lamas, NOR-2 (neuron-derived orphan receptor), a brain zinc finger protein, is highly induced during liver regeneration, FEBS Lett 372(2-3) (1995) 273-278.
[192]    P. Gervois, I.P. Torra, G. Chinetti, T. Grotzinger, G. Dubois, J.C. Fruchart, J. Fruchart-Najib, E. Leitersdorf, B. Staels, A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity, Mol Endocrinol 13(9) (1999) 1535-1549.
[193]    L. Sabatino, A. Casamassimi, G. Peluso, M.V. Barone, D. Capaccio, C. Migliore, P. Bonelli, A. Pedicini, A. Febbraro, A. Ciccodicola, V. Colantuoni, A novel peroxisome proliferator-activated receptor g isoform with dominant negative activity generated by alternative splicing, J Biol Chem 280(28) (2005) 26517-26525.
[194]    E. Goleva, L.B. Li, P.T. Eves, M.J. Strand, R.J. Martin, D.Y. Leung, Increased glucocorticoid receptor ß alters steroid response in glucocorticoid-insensitive asthma, Am J Respir Crit Care Med 173(6) (2006) 607-616.
[195]    R.H. Derijk, M.J. Schaaf, G. Turner, N.A. Datson, E. Vreugdenhil, J. Cidlowski, E.R. de Kloet, P. Emery, E.M. Sternberg, S.D. Detera-Wadleigh, A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor ß-isoform mRNA is associated with rheumatoid arthritis, J Rheumatol 28(11) (2001) 2383-2388.
[196]    C.K. Lee, E.Y. Lee, Y.S. Cho, K.A. Moon, B. Yoo, H.B. Moon, Increased expression of glucocorticoid receptor ß messenger RNA in patients with ankylosing spondylitis, Korean J Intern Med 20(2) (2005) 146-151.
[197]    C.A. Longui, A. Vottero, P.C. Adamson, D.E. Cole, T. Kino, O. Monte, G.P. Chrousos, Low glucocorticoid receptor α/ß ratio in T-cell lymphoblastic leukemia, Horm Metab Res 32(10) (2000) 401-406.
[198]    L. Pujols, J. Mullol, P. Benitez, A. Torrego, A. Xaubet, J. de Haro, C. Picado, Expression of the glucocorticoid receptor α and ß isoforms in human nasal mucosa and polyp epithelial cells, Respir Med 97(1) (2003) 90-96.
[199]    H. Shahidi, A. Vottero, C.A. Stratakis, S.E. Taymans, M. Karl, C.A. Longui, G.P. Chrousos, W.H. Daughaday, S.A. Gregory, J.M. Plate, Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia, Biochem Biophys Res Commun 254(3) (1999) 559-565.
[200]    P. Piotrowski, M. Burzynski, M. Lianeri, M. Mostowska, M. Wudarski, H. Chwalinska-Sadowska, P.P. Jagodzinski, Glucocorticoid receptor ß splice variant expression in patients with high and low activity of systemic lupus erythematosus, Folia Histochem Cytobiol 45(4) (2007) 339-342.
[201]    D.Y. Leung, Q. Hamid, A. Vottero, S.J. Szefler, W. Surs, E. Minshall, G.P. Chrousos, D.J. Klemm, Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor ß, J Exp Med 186(9) (1997) 1567-1574.
[202]    J.C. Webster, R.H. Oakley, C.M. Jewell, J.A. Cidlowski, Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative ß isoform: a mechanism for the generation of glucocorticoid resistance, Proc Natl Acad Sci U S A 98(12) (2001) 6865-6870.
[203]    Q. Xu, D.Y. Leung, K.O. Kisich, Serine-arginine-rich protein p30 directs alternative splicing of glucocorticoid receptor pre-mRNA to glucocorticoid receptor ß in neutrophils, J Biol Chem 278(29) (2003) 27112-27118.
[204]    I. Strickland, K. Kisich, P.J. Hauk, A. Vottero, G.P. Chrousos, D.J. Klemm, D.Y. Leung, High constitutive glucocorticoid receptor ß in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids, J Exp Med 193(5) (2001) 585-593.
[205]    F. Orii, T. Ashida, M. Nomura, A. Maemoto, T. Fujiki, T. Ayabe, S. Imai, Y. Saitoh, Y. Kohgo, Quantitative analysis for human glucocorticoid receptor α/ß mRNA in IBD, Biochem Biophys Res Commun 296(5) (2002) 1286-1294.
[206]    O. Tliba, G. Damera, A. Banerjee, S. Gu, H. Baidouri, S. Keslacy, Y. Amrani, Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1, Am J Respir Cell Mol Biol 38(4) (2008) 463-472.
[207]    C.C. Chung, L. Shimmin, S. Natarajan, C.L. Hanis, E. Boerwinkle, J.E. Hixson, Glucocorticoid receptor gene variant in the 3' untranslated region is associated with multiple measures of blood pressure, J Clin Endocrinol Metab 94(1) (2009) 268-276.
[208]    E.L. van den Akker, J.W. Koper, E.F. van Rossum, M.J. Dekker, H. Russcher, F.H. de Jong, A.G. Uitterlinden, A. Hofman, H.A. Pols, J.C. Witteman, S.W. Lamberts, Glucocorticoid receptor gene and risk of cardiovascular disease, Arch Intern Med 168(1) (2008) 33-39.
[209]    E.L. van den Akker, J.L. Nouwen, D.C. Melles, E.F. van Rossum, J.W. Koper, A.G. Uitterlinden, A. Hofman, H.A. Verbrugh, H.A. Pols, S.W. Lamberts, A. van Belkum, Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms, J Infect Dis 194(6) (2006) 814-818.
[210]    E. Charmandari, T. Kino, Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes, Eur J Clin Invest (in press) (2010).
[211]    G.P. Chrousos, A. Vingerhoeds, D. Brandon, C. Eil, M. Pugeat, M. DeVroede, D.L. Loriaux, M.B. Lipsett, Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease, J Clin Invest 69(6) (1982) 1261-1269.
[212]    A.C.M. Vingerhoeds, J.H.H. Thijssen, F. Schwarts, Spontaneous hypercortisolism without Cushing's syndrome, J Clin Endocrinol Metab 43 (1976) 1128-1133.
[213]    S.W. Lamberts, D. Poldermans, M. Zweens, F.H. de Jong, Familial cortisol resistance: differential diagnostic and therapeutic aspects, J Clin Endocrinol Metab 63(6) (1986) 1328-1333.
[214]    H. Nawata, K. Sekiya, K. Higuchi, K. Kato, H. Ibayashi, Decreased deoxyribonucleic acid binding of glucocorticoid-receptor complex in cultured skin fibroblasts from a patient with the glucocorticoid resistance syndrome, J Clin Endocrinol Metab 65(2) (1987) 219-226.
[215]    S. Iida, M. Gomi, K. Moriwaki, Y. Itoh, K. Hirobe, Y. Matsuzawa, S. Katagiri, T. Yonezawa, S. Tarui, Primary cortisol resistance accompanied by a reduction in glucocorticoid receptors in two members of the same family, J Clin Endocrinol Metab 60(5) (1985) 967-971.
[216]    P. Vecsei, K. Frank, D. Haack, V. Heinze, A.D. Ho, J.W. Honour, S. Lewicka, M. Schoosch, R. Ziegler, Primary glucocorticoid receptor defect with likely familial involvement, Cancer Res 49(8 Suppl) (1989) 2220s-2221s.
[217]    S.W. Lamberts, J.W. Koper, P. Biemond, F.H. den Holder, F.H. de Jong, Cortisol receptor resistance: the variability of its clinical presentation and response to treatment, J Clin Endocrinol Metab 74(2) (1992) 313-321.
[218]    D.M. Hurley, D. Accili, C.A. Stratakis, M. Karl, N. Vamvakopoulos, E. Rorer, K. Constantine, S.I. Taylor, G.P. Chrousos, Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance, J Clin Invest 87(2) (1991) 680-686.
[219]    M. Karl, S.W. Lamberts, S.D. Detera-Wadleigh, I.J. Encio, C.A. Stratakis, D.M. Hurley, D. Accili, G.P. Chrousos, Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene, J Clin Endocrinol Metab 76(3) (1993) 683-689.
[220]    M. Karl, S.W. Lamberts, J.W. Koper, D.A. Katz, N.E. Huizenga, T. Kino, B.R. Haddad, M.R. Hughes, G.P. Chrousos, Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation, Proc Assoc Am Physicians 108(4) (1996) 296-307.
[221]    D.M. Malchoff, A. Brufsky, G. Reardon, P. McDermott, E.C. Javier, C.H. Bergh, D. Rowe, C.D. Malchoff, A mutation of the glucocorticoid receptor in primary cortisol resistance, J Clin Invest 91(5) (1993) 1918-1925.
[222]    Z. Michailidou, R.N. Carter, E. Marshall, H.G. Sutherland, D.G. Brownstein, E. Owen, K. Cockett, V. Kelly, L. Ramage, E.A. Al-Dujaili, M. Ross, I. Maraki, K. Newton, M.C. Holmes, J.R. Seckl, N.M. Morton, C.J. Kenyon, K.E. Chapman, Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat diet, FASEB J 22(11) (2008) 3896-3907.
[223]    T. Kino, R.H. Stauber, J.H. Resau, G.N. Pavlakis, G.P. Chrousos, Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: Importance of the ligand-binding domain for intracellular GR trafficking, J Clin Endocrinol Metab 86(11) (2001) 5600-5608.
[224]    B.B. Mendonca, M.V. Leite, M. de Castro, T. Kino, L.L. Elias, T.A. Bachega, I.J. Arnhold, G.P. Chrousos, A.C. Latronico, Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene, J Clin Endocrinol Metab 87(4) (2002) 1805-1809.
[225]    M. Ruiz, U. Lind, M. Gafvels, G. Eggertsen, J. Carlstedt-Duke, L. Nilsson, M. Holtmann, P. Stierna, A.C. Wikstrom, S. Werner, Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance, Clin Endocrinol (Oxf) 55(3) (2001) 363-371.
[226]    E. Charmandari, T. Kino, T. Ichijo, K. Zachman, A. Alatsatianos, G.P. Chrousos, Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRαR477H and hGRαG679S associated with generalized glucocorticoid resistance, J Clin Endocrinol Metab 91(4) (2006) 1535-1543.
[227]    A. Vottero, T. Kino, H. Combe, P. Lecomte, G.P. Chrousos, A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators, J Clin Endocrinol Metab 87(6) (2002) 2658-2667.
[228]    E. Charmandari, A. Raji, T. Kino, T. Ichijo, A. Tiulpakov, K. Zachman, G.P. Chrousos, A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity, J Clin Endocrinol Metab 90(6) (2005) 3696-3705.
[229]    N. Nader, B.E. Bachrach, D.E. Hurt, S. Gajula, A. Pittman, R. Lescher, T. Kino, A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain, J Clin Endocrinol Metab 95(5) (2010) 2281-2285.
[230]    S.K. McMahon, C.J. Pretorius, J.P. Ungerer, N.J. Salmon, L.S. Conwell, M.A. Pearen, J.A. Batch, Neonatal complete generalized glucocorticoid resistance and growth hormone deficiency caused by a novel homozygous mutation in Helix 12 of the ligand binding domain of the glucocorticoid receptor gene (NR3C1), J Clin Endocrinol Metab 95(1) (2010) 297-302.
[231]    E. Charmandari, T. Kino, E. Souvatzoglou, A. Vottero, N. Bhattacharyya, G.P. Chrousos, Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype, J Clin Endocrinol Metab 89(4) (2004) 1939-1949.
[232]    E. Charmandari, T. Ichijo, W. Jubiz, S. Baid, K. Zachman, G.P. Chrousos, T. Kino, A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression, J Clin Endocrinol Metab 93(12) (2008) 4963-4968.
[233]    R. Rosmond, C. Bouchard, P. Bjorntorp, Tsp509I polymorphism in exon 2 of the glucocorticoid receptor gene in relation to obesity and cortisol secretion: cohort study, BMJ 322(7287) (2001) 652-653.
[234]    N.A. Huizenga, J.W. Koper, P. De Lange, H.A. Pols, R.P. Stolk, H. Burger, D.E. Grobbee, A.O. Brinkmann, F.H. De Jong, S.W. Lamberts, A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo, J Clin Endocrinol Metab 83(1) (1998) 144-151.
[235]    M.G. Dobson, C.P. Redfern, N. Unwin, J.U. Weaver, The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus, J Clin Endocrinol Metab 86(5) (2001) 2270-2274.
[236]    H. Russcher, E.F. van Rossum, F.H. de Jong, A.O. Brinkmann, S.W. Lamberts, J.W. Koper, Increased expression of the glucocorticoid receptor-A translational isoform as a result of the ER22/23EK polymorphism, Mol Endocrinol 19(7) (2005) 1687-1696.
[237]    E.F. van Rossum, P.G. Voorhoeve, S.J. te Velde, J.W. Koper, H.A. Delemarre-van de Waal, H.C. Kemper, S.W. Lamberts, The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults, J Clin Endocrinol Metab 89(8) (2004) 4004-4009.
[238]    E.F. van Rossum, J.W. Koper, N.A. Huizenga, A.G. Uitterlinden, J.A. Janssen, A.O. Brinkmann, D.E. Grobbee, F.H. de Jong, C.M. van Duyn, H.A. Pols, S.W. Lamberts, A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels, Diabetes 51(10) (2002) 3128-3134.
[239]    A.A. Syed, J.A. Irving, C.P. Redfern, A.G. Hall, N.C. Unwin, M. White, R.S. Bhopal, J.U. Weaver, Association of glucocorticoid receptor polymorphism A3669G in exon 9ß with reduced central adiposity in women, Obesity (Silver Spring) 14(5) (2006) 759-764.
[240]    D.M. Simpson, A.N. Bender, Human immunodeficiency virus-associated myopathy: analysis of 11 patients, Ann Neurol 24(1) (1988) 79-84.
[241]    D.P. Kotler, K. Rosenbaum, J. Wang, R.N. Pierson, Studies of body composition and fat distribution in HIV-infected and control subjects, J Acquir Immune Defic Syndr Hum Retrovirol 20(3) (1999) 228-237.
[242]    J.A. Yanovski, K.D. Miller, T. Kino, T.C. Friedman, G.P. Chrousos, C. Tsigos, J. Falloon, Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy, J Clin Endocrinol Metab 84(6) (1999) 1925-1931.
[243]    C. Hadigan, K. Miller, C. Corcoran, E. Anderson, N. Basgoz, S. Grinspoon, Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women, J Clin Endocrinol Metab 84(6) (1999) 1932-1937.
[244]    M.P. Dube, Disorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency Virus, Clin Infect Dis 31(6) (2000) 1467-1475.
[245]    G.N. Pavlakis, The molecular biology of HIV-1, in: V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.), AIDS: Diagnosis, Treatment and Prevention, Lippincott Raven, Philadelphia, 1996. pp. 45-74.
[246]    M. Emerman, HIV-1, Vpr and the cell cycle, Curr Biol 6(9) (1996) 1096-1103.
[247]    T. Kino, A. Gragerov, J.B. Kopp, R.H. Stauber, G.N. Pavlakis, G.P. Chrousos, The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor, J Exp Med 189(1) (1999) 51-62.
[248]    T. Kino, A. Gragerov, O. Slobodskaya, M. Tsopanomichalou, G.P. Chrousos, G.N. Pavlakis, Human immunodeficiency virus type-1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators, J Virol 76(19) (2002) 9724-9734.
[249]    D.N. Levy, Y. Refaeli, R.R. MacGregor, D.B. Weiner, Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1, Proc Natl Acad Sci U S A 91(23) (1994) 10873-10877.
[250]    P. Henklein, K. Bruns, M.P. Sherman, U. Tessmer, K. Licha, J. Kopp, C.M. de Noronha, W.C. Greene, V. Wray, U. Schubert, Functional and structural characterization of synthetic HIV-1 vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest, J Biol Chem 275(41) (2000) 32016-32026.
[251]    M. Mirani, I. Elenkov, S. Volpi, N. Hiroi, G.P. Chrousos, T. Kino, HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection, J Immunol 169(11) (2002) 6361-6368.
[252]    K.T. Jeang, H. Xiao, E.A. Rich, Multifaceted activities of the HIV-1 transactivator of transcription, Tat, J Biol Chem 274(41) (1999) 28837-28840.
[253]    T. Kino, G.P. Chrousos, Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes, J Endocrinol 169(3) (2001) 437-445.
[254]    T. Kino, O. Slobodskaya, G.N. Pavlakis, G.P. Chrousos, Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex, J Biol Chem 277(4) (2002) 2396-2405.
[255]    D.H. Price, P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II, Mol Cell Biol 20(8) (2000) 2629-2634.
[256]    S. Fawell, J. Seery, Y. Daikh, C. Moore, L.L. Chen, B. Pepinsky, J. Barsoum, Tat-mediated delivery of heterologous proteins into cells, Proc Natl Acad Sci U S A 91(2) (1994) 664-668.
[257]    T. Kino, M. Mirani, S. Alesci, G.P. Chrousos, AIDS-related lipodystrophy/insulin resistance syndrome, Horm Metab Res 35(3) (2003) 129-136.
[258]    C. Liu, Adenoviruses, in: R.B. Belshe (Ed.), Textbook of human virology, Mosby-Year Book, Inc., St. Louis, 1991.
[259]    D. Brockmann, H. Esche, The multifunctional role of E1A in the transcriptional regulation of CREB/CBP-dependent target genes, Curr Top Microbiol Immunol 272 (2003) 97-129.
[260]    G. Chinnadurai, CtBP, an unconventional transcriptional corepressor in development and oncogenesis, Mol Cell 9(2) (2002) 213-224.
[261]    W.J. Kovacs, D.N. Orth, The adrenal cortex, in: J. Wilson, D., D.W. Foster (Eds.), Williams Textbook of Endocrinology, W.B. Saunders Company, Philadelphia, PA, 1998. pp. 517-750.
[262]    T.P. Burris, The nuclear receptor superfamily, in: T.P. Burris, E.R.B. McCabe (Eds.), Nuclear receptors and genetic disease, Academic Press, London, 2001. pp. 1-58.
[263]    T. Kino, G.P. Chrousos, Tissue-specific glucocorticoid resistance-hypersensitivity syndromes: multifactorial states of clinical importance, J Allergy Clin Immunol 109(4) (2002) 609-613.
[264]    T. Kino, M.U. De Martino, E. Charmandari, M. Mirani, G.P. Chrousos, Tissue glucocorticoid resistance/hypersensitivity syndromes, J Steroid Biochem Mol Biol 85(2-5) (2003) 457-467.
[265]    E. Charmandari, T. Kino, G.P. Chrousos, Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms, Ann N Y Acad Sci 1024 (2004) 168-181.
[266]    T. Kino, G.P. Chrousos, Virus-mediated modulation of the host endocrine signaling systems: clinical implications, Trends Endocrinol Metab 18(4) (2007) 159-166.
[267]    E. Charmandari, T. Kino, T. Ichijo, W. Jubiz, L. Mejia, K. Zachman, G.P. Chrousos, A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance, J Clin Endocrinol Metab 92(10) (2007) 3986-3990.